Preterm birth is a major contributor to neonatal morbidity and mortality. Complications of prematurity such as bronchopulmonary dysplasia (BPD, affecting the lung), pulmonary hypertension associated with BPD (BPD-PH, heart), white matter injury (WMI, brain), retinopathy of prematurity (ROP, eyes), necrotizing enterocolitis (NEC, gut) and sepsis are among the major causes of long-term morbidity in infants born prematurely. Though the origins are multifactorial, inflammation and in particular the imbalance of pro- and anti-inflammatory mediators is now recognized as a key driver of the pathophysiology underlying these illnesses. Here, we review the involvement of the interleukin (IL)-1 family in perinatal inflammation and its clinical implications, with a focus on the potential of these cytokines as therapeutic targets for the development of safe and effective treatments for early life inflammatory diseases.
The histozoic myxozoan parasite Kudoa thyrsites causes postmortem myoliquefaction and is responsible for economic losses to salmon aquaculture in the Pacific Northwest. Despite its importance, little is known about the host-parasite relationship, including the host response to infection. The present work sought to characterize the immune response in Atlantic salmon during infection, recovery, and reexposure to K. thyrsites . After exposure to infective seawater, infected and uninfected smolts were sampled three times over 4,275 degree-days. Histological analysis revealed infection severity decreased over time in exposed fish, while in controls there was no evidence of infection. Following a secondary exposure of all fish, severity of infection in the controls was similar to that measured in exposed fish at the first sampling time but was significantly reduced in reexposed fish, suggesting the acquisition of protective immunity. Using immunohistochemistry, we detected a population of MHIIβ + cells in infected muscle that followed a pattern of abundance concordant with parasite prevalence. Infiltration of these cells into infected myocytes preceded destruction of the plasmodium and dissemination of myxospores. Dual labeling indicated a majority of these cells were CD83 + /MHIIβ + . Using reverse transcription-quantitative PCR, we detected significant induction of cellular effectors, including macrophage/dendritic cells ( mhii / cd83 / mcsf ), B cells ( igm / igt ), and cytotoxic T cells ( cd8 / nkl ), in the musculature of infected fish. These data support a role for cellular effectors such as antigen-presenting cells (monocyte/macrophage and dendritic cells) along with B and T cells in the acquired protective immune response of Atlantic salmon against K. thyrsites .
19 October 2022 in Cardiovascular Drugs and Therapy
IBD pathogenesis is underpinned by an imbalance between excess inflammation caused by effector T-cells and inadequate suppression by regulatory T-cells (Tregs). Interleukin-37 (IL-37) is a potent, anti-inflammatory cytokine that signals via its receptors IL-1R5 and IL-1R8. Hence, augmenting anti-inflammatory mechanisms that drive IL-37 expression is a strategy to control IBD-associated inflammation. However, the role of IL-37 and its receptors in T-cells remains incompletely understood. Here, we investigated T-cell expression profiles of IL-37 and its receptors to understand the drivers of dysregulated T-cell responses in IBD and develop novel, more effective therapies. T-cell subsets from healthy control (HC), Crohn’s disease (CD) and ulcerative colitis (UC) peripheral blood mononuclear cells (PBMC) and lamina propria mononuclear cells (LPMC) were assessed for expression of IL-37 and its receptors by flow cytometry. CD3+IL-1R8+ T-cell transcriptomes underwent RNA sequencing. The phenotype and suppressive capacity of Tregs supplemented with IL-37 was assessed in vitro. Our results indicate that IL-37 and its receptors were differentially expressed among PBMC and LPMC T-cell subsets in IBD patients compared to HC. Transcription signatures unique to IBD were revealed, particularly histone and mitochondrial pathways. Remarkably, culturing Tregs with IL-37 preserved FOXP3 expression and suppressiveness at a level comparable to treatment with the well-established Treg stabilizing agent rapamycin. Altogether, our study identified differences in T-cells expressing IL-37 and its receptors that are indicative of T-cell dysfunction in IBD. These findings highlight a novel and promising avenue for restoring immune homeostasis in IBD by targeting and boosting the IL-37 signalling pathway.
Perinatal inflammation, often caused by infection, is strongly linked with lifelong disability. Human and experimental studies identify interleukin-1 (IL-1), a pro-inflammatory cytokine, as a key mediator. We tested the hypothesis that systemic administration of IL-1 receptor antagonist (IL-1Ra) could attenuate cortical inflammation and improve neuronal development in late gestation fetal sheep exposed to lipopolysaccharide (LPS)-induced inflammation. Fetal sheep, instrumented for continuous EEG, were randomised to: (1) saline infusion, (2) repeated intravenous LPS + vehicle infusions or (3) the same LPS regimen plus intravenous IL-1Ra infusions one hour after each LPS dose. Four-days later, brains were examined using RNAseq, Golgi staining and immunohistochemistry. On EEG, LPS-exposure reduced beta power compared to control, particularly in REM sleep. In the somatosensory cortex, LPS-exposure decreased expression of genes involved in dendritogenesis and synaptogenesis, and increased genes involved in immune activation via LPS and IL-1 signalling. LPS-exposed fetuses had increased microglial activation and reduced neuronal arborisation. IL-1Ra treatment improved EEG band power, normalised expression of genes involved in synaptogenesis, dendritogenesis and immune activation, reduced microglial activation, and restored neuronal arborisation. In summary, IL-1Ra reduced LPS-induced inflammation and improved biomolecular, structural and functional markers of neurodevelopment. Thus, IL-1Ra may improve neurodevelopmental outcomes following perinatal infection/inflammation.
25 September 2026 in Clinical Pharmacology & Therapeutics
Anakinra, an interleukin‐1 receptor antagonist, shows promise for reducing inflammatory complications of premature birth. However, the pharmacokinetics (PK) of anakinra in neonates has not been characterized, limiting evidence‐based dosing. This study aimed to develop a population PK model for anakinra to guide dosing in preterm neonates. Data from 25 preterm neonates (median gestational age: 26.3 weeks) from a Phase I/IIa trial of intravenous anakinra (Anakinra Pilot, NCT05280340) were analyzed, with 4–8 samples collected per neonate across 0–20 days postnatal age (PNA). A population PK model was developed and dosing simulations were performed incorporating a pharmacodynamic (PD) direct effect model (I max , IC 50 ) and target exposure (AUC 0‐24h ). The data were best described by a one‐compartment model with linear elimination and a baseline component for endogenous IL‐1Ra. Allometric scaling was applied to clearance (CL) and volume of distribution (V), with a maturation function using PNA on CL to account for early age‐related pharmacokinetic changes. Estimated CL and V were 3.97 L/h/70 kg (0.15 L/h/0.9 kg) and 28.9 L/70 kg (0.37 L/h/0.9 kg). At birth, CL was ~45% of the maximal early postnatal value, achieving ~100% by day 10 PNA. Simulations suggest that an optimal intravenous dosing regimen of 0.6 mg/kg 12 hourly at birth, 0.8 mg/kg 12 hourly on PNA day 1, 1.0 mg/kg 12 hourly from PNA days 2–3 and 1.15 mg/kg 12 hourly day 4 onward. This model delivers the first critical understanding of small protein PK in premature neonates, establishing a foundation for evidence‐based dosing strategies to guide future prospective clinical trials.